Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Radiation in Operable Breast Cancer
NCT04454528Phase 2Active, not recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Dec 2020
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in breast cancer, sponsored by Abramson Cancer Center. Started Dec 2020; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04454528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04454528.